Clinical trials: Eosinophilia
Eosinophilic Esophagitis, Celiac Disease
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.
- Trial name
- NCT04593251
- Testing
- CALY-002
- Where
- 13 sites in Belgium, Finland and 3 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Calypso Biotech BV
Eosinophilic Esophagitis (EoE)
BURDEN OF ESOPHAGEAL CANCER IN EOSINOPHILIC ESOPHAGITIS (ESCAPE STUDY)
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus that can lead to symptoms such as dysphagia and food impaction.
- Trial name
- ESCAPE (NCT07102329)
- Where
- Italy
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Asthma
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
Mepolizumab is an anti-interleukin-5 ( IL-5) monoclonal antibody that neutralizes IL-5 and reduces eosinophil counts in both sputum and blood.
- Trial name
- NCT02654145
- Testing
- Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab
- Where
- 53 sites in United States, Argentina and 7 more
- Volunteers
- 145 people
- Sponsor
- GlaxoSmithKline
Esophagitis
Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis
Eosinophilic Esophagitis (EE) is a chronic inflammatory disorder of the esophagus with a constantly increasing prevalence. It has been demonstrated that the expression of the cytokine TNF-α is up regulated in EE and that this…
- Trial name
- IEE (NCT00523354)
- Testing
- Infliximab
- Where
- Switzerland
- Sponsor
- Swiss EE Study Group
Eosinophilic Esophagitis (EoE)
A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.
- Trial name
- NCT02605837
- Testing
- Oral Budesonide Suspension (OBS)
- Where
- 77 sites in United States
- Volunteers
- 318 people
- Sponsor
- Shire
Esophageal Stricture, Eosinophilic Esophagitis
EndoFLIP Use in Upper GI Tract Stenosis
The purpose of this study is to investigate the use of a functional luminal imaging probe to characterize benign esophageal luminal strictures before and after dilation and identify predictors of response to therapy.
- Conditions
- Esophageal Stricture, Eosinophilic Esophagitis, Zenkers Diverticulum, Schatzki Ring
- Trial name
- EndoFLIP (NCT02354716)
- Testing
- EndoFLIP
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Eosinophilic Esophagitis
Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
This study is being done to see if allergy patch testing (APT) can help predict effective dietary therapy in patients with eosinophilic esophagitis.
- Trial name
- EoE (NCT02227836)
- Testing
- Allergy Patch Testing
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Eosinophilic Esophagitis
Short Duration 6Fed Sponge For EoE Patients
This research is being done to see if the investigators can use the cytosponge or esophacap (depending on availability) to determine if shorter duration SFED (two weeks versus six weeks) would have equal results.
- Trial name
- NCT03354221
- Testing
- Cytosponge, Diet, EEsAI Pro
- Where
- United States
- Sponsor
- Mayo Clinic
Eosinophilic Esophagitis (EoE)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus.
- Trial name
- NCT06665971
- Testing
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms.
- Trial name
- NCT01404832
- Testing
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dallas VA Medical Center
Eosinophilic Esophagitis
Risk Factors and Biomarkers for Diagnosis and Treatment of EoE
Purpose: To validate our previously developed model of risk factors for diagnosis of eosinophilic esophagitis (EoE), and to assess the utility of serum levels of biomarkers in diagnosis and monitoring of treatment of EoE.
- Trial name
- NCT01988285
- Testing
- Specimen Collection, Questionnaires
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Esophagitis
Tolerability of Goat Milk Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger
Eosinophilic esophagitis (EoE) is a chronic immune mediated disease characterized by eosinophilic infiltration in esophageal epithelium and resulting in esophageal dysfunction.
- Trial name
- NCT05180578
- Testing
- Goat milk diet
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Shaare Zedek Medical Center
Asthma; Eosinophilic, Airway Remodeling
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response.
- Trial name
- BREATH (NCT06288516)
- Testing
- Benralizumab 30 mg/ml
- Where
- Greece
- Volunteers
- 36 people
- Sponsor
- Aristotle University Of Thessaloniki
Eosinophilic Esophagitis
Budesonide for Eosinophilic Esophagitis
Eosinophilic Esophagitis (EE) is a chronic, T-helper 2 cell (TH2) - type inflammatory disorder of the esophagus with a rapidly increasing prevalence.
- Trial name
- BEE (NCT00271349)
- Testing
- Budesonide
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Swiss EE Study Group
Eosinophilic Esophagitis
Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
A phase I/II, multicenter, double-blind, parallel, randomized trial to assess pharmacokinetics, efficacy, tolerability and safety of different budesonide oral gel doses in adults subjects of both genders with eosinophilic…
- Trial name
- BESIDE (NCT05214599)
- Testing
- Budesonide Gel
- Sponsor
- Bazell Pharma AG
Hypereosinophilic Syndrome
Eosinophilia Diagnosis
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
- Trial name
- EOSINOPHILIM (NCT02581514)
- Testing
- Scheduled exams and diagnosis
- Where
- France
- Volunteers
- 53 people
- Sponsor
- University Hospital, Limoges
Eosinophilic Esophagitis
Esophageal Absorption in EoE
To determine how the esophagus in active and inactive stages of eosinophilic esophagitis tranmit fluids.
- Trial name
- EoE (NCT02314455)
- Testing
- D-xylose
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Eosinophilic Esophagitis
Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis
The purpose of this study is to evaluate the efficacy of three doses of Florence oral suspension on changes of eosinophilic infiltration in esophageal biopsies.
- Trial name
- NCT02873468
- Testing
- Florence 30 μg/mL, Florence 60 μg/mL, Florence 90 μg/mL
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- EMS
Severe Eosinophilic Asthma
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Benralizumab is a humanised, afucosylated, monoclonal antibody against the interleukin (IL)-5 receptor (IL-5R) α subunit that induces direct, rapid, and near-complete depletion of eosinophils in blood, airway tissue, and bone…
- Trial name
- NCT05271526
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Lung Adenocarcinoma, Malignant Pleural Effusions (Mpe)
Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
- Trial name
- NCT07636252
- Testing
- Non-Interventional Study
- Where
- Israel
- Volunteers
- 400 people
- Sponsor
- Sheba Medical Center